Show results for
Refine by
Therapeutic Potential Suppliers Serving Moldova
43 companies found
based inOttawa, SWITZERLAND
Orion Biotechnology is unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs) with a novel drug modality, proven discovery platform and best-in-class molecules. The company is advancing a diversified ...
Orion’s platform and science unlocks the therapeutic potential of GPCR targets across a broad range of medical needs. Our approach allows us to focus our discovery and development efforts ...
based inLausanne, SWITZERLAND
Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to improve patient outcomes and quality of life in oncology and bacterial infections. Our main activities include drug development, drug ...
based inDijon, FRANCE
Oncodesign is a biopharmaceutical company that offers you powerful technologies and tools to guide you through the development of your drug, from medicinal chemistry to drug candidate. Our therapeutic areas are expanding. In addition to oncology, ...
EXPLORE, a new service to identify and validate therapeutic targets, primarily cancer treatments – an area of expertise and excellence at Oncodesign to discover and investigate preclinical proofs of concept involving a wide variety of ...
based inSchlieren, SWITZERLAND
Based on our research, we believe that the common denominator underlying each intestinal microbiome is a network of interconnected, interdependent and metabolic functions that are essential for the host and the microbiome. PharmaBiome has developed ...
Solid research shows that the smallest relevant biological unit of the microbiome is function, delivered by a network of intestinal bacteria. Bacteria need to interact in a functional network and achieve a balance so that the microbiome can ...
based inMechelen, BELGIUM
Galapagos discovers, develops and commercializes small molecule medicines with novel modes of action. Our pipeline comprises discovery through to Phase 3 programs in inflammation, fibrosis, and other indications. Our first medicine is approved and ...
The SIK program is a strategic effort to develop assets inhibiting salt-inducible kinases (SIK) as a novel target class in inflammation which we discovered with our proprietary target discovery platform. These molecules inhibit the different members ...
based inBrisbane City, AUSTRALIA
Microba’s precise microbiome analysis is built on the expertise of our innovative team at the leading edge of microbiome science. Our approach to microbiome analysis is enabling new discoveries and advancing the understanding of the microbiome in ...
Developing novel therapeutics from the human microbiome; The uncultured portion of the human gut microbiome, which is the majority of microbial species, represents untapped therapeutic opportunity. Microba has established a platform for drug ...
based inHaifa, ISRAEL
Pluristem Therapeutics Inc. is a clinical-stage regenerative medicine company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for conditions such as inflammation, muscle injuries, ...
PLX-R18 cells release a combination of therapeutic proteins in response to a damaged or poorly functioning hematopoietic system; this system creates the blood cells that protect us from infection, uncontrolled bleeding and anemia. PLX-R18 is ...
based inMalvern, PENNSYLVANIA (USA)
Since our founding in 2001, we have had one singular obsession: We strive to give our clients a personalized and collaborative research experience. We are here to help you find the answers you need to develop the best possible drug candidate for ...
ASH1L is a large , multi-domain protein associated with actively transcribed regions of chromatin, ASH1L is the human homolog of Drosophila Ash1, a Trithorax group protein. Like its counterpart in Drosophila, ASH1L contains a SET histone ...
based inBoston, MASSACHUSETTS (USA)
Neoclease is at the forefront of advancing gene editing technologies with a mission to transform healthcare by curing genetic diseases rather than just treating them. Utilizing a bespoke approach, the company develops tailored nucleases designed to ...
The focus on innovation extends to the creation of comprehensive nuclease libraries, ensuring a wide range of tools for various applications. The company aims to shift the paradigm in therapeutic development, moving towards ...
based inPasadena, CALIFORNIA (USA)
Bench Chemicals, aka. BenchChem, is a leading supplier of high-quality chemicals and biochemicals for laboratory and R&D use. Our mission is to provide scientists and researchers worldwide with a one-stop source for innovative and basic chemicals ...
Nevadensin is a novel small molecule that has been studied for its potential therapeutic applications in medicine. It is a member of the polyphenol family and has a unique structure that makes it attractive for use ...
based inVerona, ITALY
At Sibylla Biotech, we face the complexity of drug discovery with the power of an innovative approach for meeting unmet medical needs. Born out of a scientific challenge, the PPI-FIT protocol (Pharmacological Protein Inactivation by Folding ...
In Silico: Identifying small molecules able to revolutionize drug discovery. The PPI-FIT technology allows the exploration of unique pharmacological targets represented by protein folding intermediates. This places Sibylla Biotech in the exclusive ...
based inObninsk, RUSSIA
Our Company started a few years ago when specialists in the area of Medicine, engineering and business got together and decided to create REAFIT, a company specialized in a wide range of rehabilitation equipment and assistive devices. Yuri's ...
Multi-functional equipment, which may be used in one room for comprehensive rehabilitation. Built-in verticalizer, power stations, unloading and slider systems provide for a wide range of work with different categories of patients suffering ...
based inGuildford, UNITED KINGDOM
Futura Medical is a pharmaceutical company developing a portfolio of innovative products based on our proprietary, transdermal DermaSys technology. Futura Medical is an innovative R&D company with a pipeline of products in late stage development. ...
Joint venture collaboration. Early development stage completed. IP application filed. Advisers retained to explore commercial ...
based inHackensack, NEW JERSEY (USA)
At Champions Oncology, we are passionate about aiding the pharmaceutical industry in developing the innovative treatments of today and the cures for tomorrow. We provide end-to-end research and development solutions throughout the drug development ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
TP-3654 is an oral investigational inhibitor of PIM kinases, which has potential antitumor and anti-fibrotic effects through multiple pathways, including induction of ...
based inNantes, FRANCE
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. Based in Nantes (Head Office) and Paris, OSE Immunotherapeutics ...
Most anti-inflammatory agents act using a mechanism that blocks pro-inflammation pathways. In contrast, OSE Immunotherapeutics is developing OSE-230 as a first-in-class therapeutic agent with the potential to ...
based inCambridge, MASSACHUSETTS (USA)
The exponential growth of biomedical data, driven by the adoption of electronic medical records (EMRs), provides an unprecedented opportunity to create transformative technologies and products in healthcare. nference partners with medical centers to ...
Our scientists use the nference platform and data in collaboration with your teams to tackle your most important questions and challenges. nference is creating the largest labeled EMR dataset in healthcare. EMR data contains longitudinal real-world, ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 ...
based inPlanegg, GERMANY
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines. At MorphoSys, our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical ...
Tafasitamab (MOR208) is a humanized FC-modified CD19 targeting immunotherapy in clinical development for the treatment of B cell malignancies. CD19 is broadly expressed on the surface of B cells. It is therefore considered as a potential target for ...
based inChicago, ILLINOIS (USA)
Our company began as Nymirum. As protein drug discovery continued to exhaust low-hanging fruits, we founded Nymirum in 2009 to tackle a new and challenging frontier filled with untapped therapeutic potential: targeting RNA with small molecules. We ...